Institutional members access full text with Ovid®

Lymphoma Drug Receives Accelerated Approval

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: November 2011 - Volume 111 - Issue 11 - p 24
doi: 10.1097/01.NAJ.0000407288.47749.4c
Drug Watch

* Brentuximab (Adcetris), an antibody–drug conjugate, has been given accelerated approval to treat Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.

* The drug label warns of the following serious adverse effects: peripheral neuropathy, neutropenia, infusion reactions, tumor lysis syndrome, Stevens–Johnson syndrome, progressive multifocal leukoencephalopathy, and teratogenesis.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2011 Lippincott Williams & Wilkins, Inc.